Acute intermittent porphyria: a diagnostic challenge.

Karol Bigosiński(1 Military Clinical Hospital with Outpatient Clinic), Marek Hus(Medical University of Lublin), Aneta Szudy‐Szczyrek(Medical University of Lublin), Maciej Dubaj(Medical University of Lublin)
Acta Haematologica Polonica
August 31, 2024
10.5603/ahp.101063
Cited by 4

Related Papers

Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
|New England Journal of Medicine|2024|162
Thalidomide treatment of resistant or relapsed multiple myeloma patients.
|PubMed|2001|85
Therapy‐related peripheral neuropathy in multiple myeloma patients
|Hematological Oncology|2014|70
Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis
|Leukemia|2022|63
Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma
|Annals of Hematology|2011|62